


INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) AUG 02 2004 PATENT & TRADEMARK OFFICE		ATTY. DOCKET NO. PC25408A		SERIAL NO. 10762,959		
		APPLICANT Philip A. Carpino				
		FILING DATE 1/21/04		GROUP 1614		
U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
SM	US 20010027193 A1	10/04/01	Achard, et al.			
SM	US 20010053788 A1	12/20/01	Lange, et al.			
SM	US 20020019383 A1	02/14/02	Achard, et al.			
SM	US 20020019421 A1	02/14/02	Biberman, et al.			
SM	US 20020035102 A1	03/21/02	Achard, et al.			
SM	US 20020091114 A1	07/11/02	Plot-Grosjean, et al.			
SM	US 20020119972 A1	08/29/02	Leftheris, et al.			
SM	US 20020128302 A1	09/12/02	Maruani, et al.			
SM	US 20020188007 A1	12/12/02	Barth, et al.			
SM	US 20030003145 A1	01/02/03	Abramovici, et al.			
SM	US 20030055033 A1	03/20/03	Achard, et al.			
SM	US 20030114495 A1	06/19/03	Finke, et al.			
SM	US 20030139386 A1	07/24/03	Cote, et al.			
SM	US 20030199536 A1	10/23/03	Thomas, et al.			
SM	US 20040077650 A1	4/22/04	Dow			
SM	US 20040092520 A1	5/12/04	Griffith			
SM	US 4,925,846	05/15/90	Deacon, et al.			
SM	US 4,944,790	07/31/90	Moser, et al.			
SM	US 5,134,142	07/28/92	Matsuo, et al.			
SM	US 5,462,960	10/31/95	Barth, et al.			
SM	US 5,596,106	01/21/97	Cullinan, et al.			
SM	US 5,624,941	04/29/97	Barth, et al.			
SM	US 5,744,491	04/28/98	Boigegrain, et al.			

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC25408A		SERIAL NO. 10/762,959			
		APPLICANT Philip A. Carpino					
		FILING DATE 1/21/04		GROUP 1614			
SM	US 5,744,493	04/28/98	Boigegrain, et al.				
SM	US 5,747,524	05/05/98	Cullinan, et al.				
SM	US 5,925,768	07/20/99	Barth, et al.				
SM	US 6,028,084	02/22/00	Barth, et al.				
SM	US 6,100,259	08/08/00	Xiang, et al.				
SM	US 6,344,474 B1	02/05/02	Maruani, et al.				
SM	US 6,355,631 B1	03/12/02	Bouchard, et al.				
SM	US 6,432,984 B1	08/13/02	Barth, et al.				
SM	US 6,476,060 B2	11/05/02	Lange, et al.				
SM	US 6,479,479 B2	11/12/02	Achard, et al.				
SM	US 6,509,367 B1	01/21/03	Martin, et al.				
SM	US 6,518,264 B2	02/11/03	Achard, et al.				
SM	US 6,566,356 B2	05/20/03	Achard, et al.				
<b>FOREIGN PATENT DOCUMENTS</b>							
DOCUMENT NUMBER		DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
SM	CA 2,387,138 equiv. to WO 01/028557 A1	04/26/01	CA				
SM	US 2003087933 equiv. to WO 01/58450 A2	08/16/01	PCT				
SM	US 5051518 equiv. to EP 293,220 B1	8/31/94	EP				
SM	US 6642258 equiv. to WO 01/24798 A1	04/12/01	PCT				
SM	WO 00/15609 A1	05/23/00	PCT				X
SM	WO 01/029007 A1	04/26/01	PCT				
SM	WO 01/032629 A1	05/10/01	PCT				X
SM	WO 01/032663 A2	05/10/01	PCT				X
SM	WO 01/85092 A2	11/15/01	PCT				X
SM	WO 02/076949 A1	10/03/02	PCT				

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC25408A		SERIAL NO. 10/762,959			
		APPLICANT Philip A. Carpino					
		FILING DATE 1/21/04		GROUP 1614			
SM	WO 03/006007 A1	01/23/03	PCT				
SM	WO 03/007887 A2	01/30/03	PCT				
SM	WO 03/018060 A1	03/06/03	PCT				X
SM	WO 03/020217 A2	03/13/03	PCT				
SM	WO 03/020314 A1	03/13/03	PCT				X
SM	WO 03/026647 A1	04/03/03	PCT				
SM	WO 03/026648 A1	04/03/03	PCT				
SM	WO 03/027069 A1	04/03/03	PCT				
SM	WO 03/027076 A2	04/03/03	PCT				
SM	WO 03/027114 A1	04/03/03	PCT				
SM	WO 03/040107 A1	05/15/03	PCT				
SM	WO 03/051850 A1	06/26/03	PCT				
SM	WO 03/051851 A1	06/26/03	PCT				
SM	WO 03/075660 A1	09/18/03	PCT				
SM	WO 03/077847 A2	09/25/03	PCT				
SM	WO 03/078413 A1	09/25/03	PCT				
SM	WO 03/082190 A2	10/09/03	PCT				
SM	WO 03/082191 A2	10/09/03	PCT				
SM	WO 03/082256 A2	10/09/03	PCT				X
SM	WO 03/082833 A1	10/09/03	PCT				X
SM	WO 03/084943 A2	10/16/03	PCT				X
SM	WO 03/086288 A2	10/23/03	PCT				
SM	WO 03/087037 A1	10/23/03	PCT				
SM	WO 04/012617 A2	02/12/04	PCT				
SM	WO 96/02248 A1	02/01/96	PCT				

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC25408A	SERIAL NO. 10/762,959
		APPLICANT Philip A. Carpino	
		FILING DATE 1/21/04	GROUP 1614
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
SM		Tzavara, E.T., et al., "The CB1 Receptor Antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: Implications for Therapeutic Actions," <u>J Pharmacol</u> , <b>138</b> , 544-553 (2003).	
SM		Racz, I., et al., "A Critical Role for the Cannabinoid CB1 Receptors in Alcohol Dependence and Stress-Stimulated Ethanol Drinking," <u>J Neurosci</u> , <b>23</b> (6), 2453-2458 (2003).	
SM		Croci, T., et al., "Role of Cannabinoid CB1 Receptors and Tumor Necrosis Factor- $\alpha$ in the gut and systemic anti-inflammatory activity of SR 141716 (Rimonabant) in rodents," <u>Brit J Pharmacol</u> , <b>140</b> , 115-122 (2003).	
SM		DaSilva, G.E., et al., "Potentiation of Penile Erection and Yawning Responses to Apomorphine by Cannabinoid Receptor Antagonists in Rats," <u>Neurosci Lett</u> , <b>349</b> , 49-52 (2003).	
SM		Wang, L., et al., "Endocannabinoid Signaling via Cannabinoid Receptor 1 is Involved in Ethanol Preference and its Age-Dependent Decline in Mice," <u>PNAS</u> , <b>100</b> (3), 1393-1398 (2003).	
SM		Ruiu, S., et al., "Synthesis and Characterization of NESS 0327: A Novel Putative Antagonist of the CB1 Cannabinoid Receptor," <u>J Pharmacol Exp Therap</u> , <b>306</b> , 363-370 (2003).	
SM		Howlett, A.C., et al., "International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors," <u>Pharmacol Rev</u> , <b>54</b> , 161-202 (2002).	
SM		Gomez, R., et al., "A Peripheral Mechanism for CB1 Cannabinoid Receptor-Dependent Modulation of Feeding," <u>J. Neurosci</u> , <b>22</b> (21), 9612-9617 (2002).	
SM		Wiley, J.L., et al., "Novel Pyrazole Cannabinoids: Insights into CB1 Receptor Recognition and Activation," <u>J Pharmacol Exp Therap</u> , <b>296</b> (3), 1013-1022 (2001).	
SM		Lellemund, F., et al., "Effects of CB1 Cannabinoid Receptor Blockade on Ethanol Preference After Chronic Ethanol Administration," <u>Alcohol Clin Exp Res</u> , <b>25</b> (9), 1317-1323 (2001).	
SM		Pertwee, R.G., "Cannabinoids and the Gastrointestinal Tract," <u>Gut</u> , <b>48</b> , 859-867 (2001).	
SM		Pertwee, R.G., "Cannabinoid Receptor Ligands: Clinical and Neuropharmacological Considerations, Relevant to Future Drug Discovery and Development," <u>Exp. Opin. Invest. Drugs</u> , <b>9</b> (7), 1573-1571 (2000).	
SM		Hungund, B.L and B.S. Basavarajappa, "Are Anadamide and Cannabinoid Receptors involved in Ethanol Tolerance? A Review of the Evidence," <u>Alcohol &amp; Alcoholism</u> , <b>35</b> (2) 126-133, (2000).	
SM		Freedland, C.S., et al., "Effects of SR141716A, a Central Cannabinoid Receptor Antagonist, on Food-maintained Responding," <u>Pharmacol Biochem Behav</u> , <b>67</b> , 265-270 (2000).	
SM		Lan, R., et al., "Structure-Activity Relationships of Pyrazole Derivatives as Cannabinoid Receptor Antagonists" <u>J. Med. Chem</u> , <b>42</b> , 769-776 (1999).	
SM		Pertwee, R.G., "Pharmacology of Cannabinoid Receptor Ligands" <u>Curr Med Chem</u> , <b>6</b> , 635-664 (1999).	
SM		Basavarajappa, B.S., et al., "Chronic Ethanol Administration Down-regulates Cannabinoid Receptors in Mouse Brain Synaptic Plasma Membrane," <u>Brain Res</u> , <b>793</b> , 212-218 (1998).	
SM		Thomas, B.F., et al., "Comparative Receptor Binding Analyses of Cannabinoid Agonists and Antagonists," <u>J Pharmacol Exp Therap</u> , <b>285</b> , 285-292 (1998).	
SM		Colombo, G., et al., "Appetite Suppression and Weight Loss after the Cannabinoid Antagonist SR141716," <u>Life Sci.</u> , <b>63</b> , PL113-PL117 (1998);	
SM		Simiand, J., et al., "SR141716, a CB1 Cannabinoid Receptor Antagonist, Selectively Reduces Sweet Food Intake in Marmose," <u>Behav. Pharmacol.</u> , <b>9</b> , 179-181 (1998).	
SM		Chaperon, F., et al., "Involvement of Central Cannabinoid (CB1) Receptors in the Establishment of Place Conditioning in Rats," <u>Psychopharmacology</u> , <b>135</b> , 324-332 (1998).	
SM		Arnone, M., et al., "Selective Inhibition of Sucrose and Ethanol Intake by SR141716, an Antagonist of Central Cannabinoid (CB1) Receptors," <u>Psychopharmacol</u> , <b>132</b> , 104-106 (1997).	

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC25408A	SERIAL NO. 10/762,959
		APPLICANT Philip A. Carpino	
		FILING DATE 1/21/04	GROUP 1614
SM		Savontaus, E., et al., "Anti-Obesity Effect of MPV-1743 A III, a Novel Imidazoline Derivative, in Genetic Obesity," <u>Eur J Pharmacol</u> , <b>328</b> , 207-215 (1997).	
SM		Sanudo-Pena, M.C., et al., "Endogenous Cannabinoids as an Aversive or Counter-rewarding System in the Rat," <u>Neurosci Lett</u> , <b>223</b> , 125-128 (1997).	
SM		Gifford, A.N., et al., "Electrically Evoked Acetylcholine Release from Hippocampal Silices is Inhibited by the Cannabinoid Receptor Agonist, WIN 55212-2 and is Potentiated by the Cannabinoid Antagonist, SR 141716A," <u>J Pharmacol Exp Ther</u> , <b>277</b> , 1431-1436 (1996).	
SM		Compton, D.R., et al., "In Vivo Characterization of a Specific Cannabinoid Receptor Antagonist (SR141716A); Inhibition of Delta-9-Tetrahydrocannabinol-Induced Responses and Apparent Agonist Activity," <u>J Pharmacol Exp Ther</u> , <b>277</b> , 586-594 (1996).	
SM		Mansbach, R.S., et al., "Effects of the Cannabinoid CB1 Receptor Antagonist SR141716A on the Behavior of Pigeons and Rats," <u>Psychopharmacology</u> , <b>124</b> , 315-322 (1996).	
SM		Lichtman, A.H., et al., "Delta-9-Tetrahydrocannabinol Impairs Spatial Memory through a Cannabinoid Receptor Mechanism," <u>Psychopharmacology</u> , <b>126</b> , 125-131 (1996).	
SM		Perio, A., et al., "Central Mediation of the Cannabinoid Cue: Activity of a Selective CB1 Antagonist, SR141716A," <u>Behavioral Pharmacology</u> , <b>7</b> , 65-71 (1996).	
SM		Rinaldi-Carmona, M., et al., "Biochemical and Pharmacological Characterization of SR141716A, The First Potent and Selective Brain Cannabinoid Receptor Antagonist," <u>Life Sci</u> , <b>56</b> , 1941-1947 (1995).	
SM		Pertwee, R., et al., "AM630, A Competitive Cannabinoid Receptor Antagonist," <u>Life Sci</u> , <b>56</b> , 1949-1955 (1995).	
SM		Rinaldi-Carmona, M., et al., "SR141716A, a Potent and Selective Antagonist of the Brain Cannabinoid Receptor," <u>FEBS Letters</u> , <b>350</b> , 240-244 (1994).	
SM		Dutta, A., et al., "The Synthesis and Pharmacological Evaluation of the Cannabinoid Antagonist SR 141716A," <u>Med. Chem. Rev.</u> <b>5</b> , 54-62 (1994).	
SM		Drummond, J., et al., "Evaluation and Synthesis of Aminohydroxyisoxazoles and Pyrazoles as Potential Glycine Agonists," <u>J. Med. Chem.</u> <b>32</b> , 2116-2128 (1989).	
SM		Murray, W., et al., "A Simple Regioselective Synthesis of Ethyl 1,5-Diarylpyrazole-3-carboxylates" <u>J. Heterocyclic Chem.</u> <b>26</b> , 1389 (1989).	
SM		Dewey, W.L. "Cannabinoid Pharmacology," <u>Pharmacological Reviews</u> , <b>38</b> (2) 151-178 (1986).	
SM		Tewari, R.S., et al., "1,3-Dipolar Cycloaddition and Nucleophilic Substitution Reactions of C-Acetyl and C-Ethoxycarbonyl Derivative of Hydrazidoyl Bromides" <u>Tetrahedron</u> , <b>39</b> (1) 129-136 (1983).	
SM		Birkofer, L. and K. Richtzenhain, "Silyl-Derivate von Pyrazol, Isoxazol und 1,2,3-Triazol" <u>Chem. Ber.</u> <b>112</b> , 2829-2836 (1979).	
SM		Franke, H. et al., "Polare Cycloadditionen von elektronenreichen Mehrfach-bindungssystemen an 1,3,4-oxadiazolium-Salze: Synthese von 3aH-[1,3,4]Oxadiazolo[3,2-a]chinolinen" <u>Chem. Ber.</u> <b>112</b> , 3623-3636 (1979).	
SM		Sucrow, W., et al., "Bimolekulare Cyclisierung von 2-(1-Methylhydrazino)maleinsäure-dimethylester" <u>Chem. Ber.</u> <b>112</b> , 1712-1718 (1979).	
EXAMINER /Susanna Moore/ DATE CONSIDERED 08/25/2006			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			



**SERIAL NO.10/762,959**

FILING DATE 1/21/04

**GROUP 1614**

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLÁSS	TRANSLATION	
													YES	NO
SM	WO	03	0	9	5	4	5	5	11/20/03	International	C07D			
SM	EP	1	3	5	4	8	8	4	10/22/03	European	C07D			
SM	WO	02	0	5	3	5	6	5	7/11/02	International	C07D		X	

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

SM			U.S. Patent Application Publication No. 2004/0072833, published April 15, 2004, equivalent to WO02053565.

**EXAMINER**

/Susanna Moore/

DATE CONSIDERED

08/25/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE CITATION</b> <i>(Use several sheets if necessary)</i>				ATTY. DOCKET NO. PC25408A				SERIAL NO. 10/762,959				
				APPLICANT David A. Griffith								
				FILING DATE January 21, 2004				GROUP 1625				
<b>U.S. PATENT DOCUMENTS</b>												
EXAMINER INITIAL		DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
SM	US	2004/0092520						5/13/04	Griffith	514	242	
<b>FOREIGN PATENT DOCUMENTS</b>												
DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
												YES NO
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>												
SM		Beardsley, P.M., et al., <u>Behavioural Pharmacology</u> , "Current Evidence Supporting a Role of Cannabinoid CB1 Receptor (CB1R) Antagonists as Potential Pharmacotherapies for Drug Abuse Disorders", Vol. 16, pages 275-296 (2005)										
SM		Bermudez-Siva, F., et al., <u>Journal of Pharmacology</u> , "Activation of Cannabinoid CB1 Receptors Induces Glucose Intolerance in Rats", Vol. 531, pages 282-284 (2008)										
SM		Brittain, H.G., <u>Drugs and the Pharmaceutical Sciences</u> , "Polymorphism in Pharmaceutical Solids", Vol. 95, pages 202-207 (1999)										
SM		Brodie, B.B., <u>Life Sciences</u> , "Rimonabant: The First Therapeutically Relevant Cannabinoid Antagonist", Vol. 77, pages 2339-2350 (2005)										
SM		Cao, X., et al., "A Selective Cannabinoid CB1 Antagonist Increases Levodopa Responses in Parkinsonian Monkeys"										
SM		Chambers, A.P., et al., <u>Physiology &amp; Behavior</u> , "Cannabinoid (CB1) Receptor Antagonist, AM 251, causes a Sustained Reduction of Daily Food Intake in the Rat", Vol. 82, pages 863-869 (2004)										
SM		Chaperon, F., et al., <u>Psychopharmacology</u> , "Involvement of Central Cannabinoid (CB1) Receptors in the Establishment of Place Conditioning in Rats", Vol. 135, pages 324-332 (1998)										
SM		Cohen, C., et al., <u>Behavioural Pharmacology</u> , "SR141716, A Central Cannabinoid (CB1) Receptor Antagonist, Blocks the Motivational and Dopamine-Releasing Effects of Nicotine in Rats", Vol. 13, pages 451-463 (2002)										
SM		Croci, T., et al., <u>British Journal of Pharmacology</u> , "Role of Cannabinoid CB1 Receptors and Tumor Necrosis Factor - $\alpha$ in the Gut and Systemic Anti-Inflammatory Activity of SR 141716 (Rimonabant) in Rodents", Vol. 140, pages 115-122 (2003)										
SM		De Vries, T.J., et al., <u>TRENDS in Pharmacological Sciences</u> , "Cannabinoid CB1 Receptors Control Conditioned Drug Seeking", Vol. 26 No. 8, pages 420-426 (2005)										
SM		Di Marzo, V., <u>TRENDS in Pharmacological Sciences</u> , "A Brief History of Cannabinoid and Endocannabinoid Pharmacology as Inspired by the Work of British Scientists", Vol. 20 No. 20 pages 1-7 (2006)										
SM		Di Marzo, V., et al., <u>The FASEB Journal</u> , "Enhanced Levels of Endogenous Cannabinoids in the Globus Pallidus are Associated with a Reduction in Movement in an Animal Model of Parkinson's Disease", Vol. 14, pages 1432-1438 (2000)										
SM		Fernandez, J.R., et al., <u>Current Opinion in Investigational Drugs</u> , "Rimonabant Sanofi-Synthelabo", Vol. 5, No. 4, pages 430-435 (2004)										
SM		Ferrer, B., et al., <u>European Journal of Neuroscience</u> , "Effects of Levodopa on Endocannabinoid Levels in Rat Basal Ganglia: Implications for the Treatment of Levodopa-Induced Dyskinesias", Vol. 18, pages 1607-1614 (2003)										
SM		Griebel, G., et al., <u>Biol. Psychiatry</u> , "Effects of the Cannabinoid CB1 Receptor antagonist Rimonabant in Models of Emotional										

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC25408A	SERIAL NO. 10/762,959
		APPLICANT David A. Griffith	
		FILING DATE January 21, 2004	GROUP 1625
		Reactivity in Rodents", Vol. 57, pages 261-267 (2005)	
SM		Lange, J., et al., <u>Drug Discovery Today</u> "Medicinal Chemistry Strategies to CB1 Cannabinoid Receptor Antagonists", Vol. 10, No. 10, pages 693-702 (2005)	
SM		Le Foll, B., et al., <u>NeuroReport</u> , "Reimonabant, a CB1 Antagonist, Blocks Nicotine-Conditioned Place Preferences", Vol. 15, No. 13, pages 2139-2143 (2004)	
SM		Mansbach, R.S., et al., <u>Psychopharmacology</u> , "Effects of the Cannabinoid CB1 Receptor Antagonist SR141716A on the Behaviour of Pigeons and Rats", Vol. 124, pages 315-322 (1996)	
SM		Mas-Nieto, M., et al., <u>British Journal of Pharmacology</u> , "Reduction of Opioid Dependence by the CB1 antagonist SR141716A in Mice: Evaluation of the Interest in Pharmacology of Opioid Addiction", Vol. 132, pages 1809-1816 (2001)	
SM		Mechoulam, R., et al., <u>TRENDS in Pharmacological Sciences</u> , "Cannabis and Alcohol - A Close Friendship", Vol. 24, No. 6, pages 266-268 (2003)	
SM		Muccioli, G.G., et al., <u>Current Medicinal Chemistry</u> , "Current Knowledge on the Antagonists and Inverse Agonists of Cannabinoid Receptors", Vol. 12, pages 1361-1394 (2005)	
SM		Pagotto, U., et al., <u>Endocrine Reviews</u> , "The Emerging Role of the Endocannabinoid System in Endocrine Regulation and Energy Balance", Vol. 27, No. 1, pages 73-100 (2006)	
SM		Pagotto, U., et al., <u>Current Opinion in Endocrinology &amp; Diabetes</u> , "the Role of the Endocannabinoid Pathway in Metabolism and Diabetes", Vol. 13, pages 171-178 (2006)	
SM		Poncellet, M., et al., <u>Psychopharmacology</u> , "Blockade of Cannabinoid (CB1) Receptors By SR 141716 Selectively Antagonizes Drug-Induced Reinstatement of Exploratory Behaviour in Gerbils", Vol. 144, pages 144-150 (1999)	
SM		Sanudo-Pena, M., et al., <u>Neuroscience Letters</u> , "Endogenous Cannabinoids As an Aversive or Counter-Rewarding System in the Rat", Vol. 223, pages 125-128 (1997)	
SM		Smith, R.A., et al., <u>IDrugs</u> , "Recent Advances in the Research and Development of CB1 Antagonists", Vol. 8, No. 1, pages 53-66 (2005)	
SM		Thakur, G.A., et al., <u>Mini-Reviews in Medicinal Chemistry</u> , "CB1 Cannabinoid Receptor Ligands", Vol. 5, pages 831-840 (2005)	
SM		Van Der Stelt, M., et al., <u>The FASEB Journal</u> , "A Role For Endocannabinoids in the Generation of Parkinsonism and Levodopa-Induced Dyskinesia in MPTP-Lesioned Non-Human Primate Models of Parkinson's Disease", Vol. 19, pages 1140-1142 (2005)	
SM		Van Gaal, L., et al., <u>Lancet</u> , "Effects of the Cannabinoid-1 Receptor Blocker Rimonabant on Weight Reduction and Cardiovascular Risk Factors in Overweight Patients: 1-year Experience from the RIO-Europe Study", Vol. 365, pages 1389-1397 (2005)	
SM		Wilkin, J.M., et al., <u>TRENDS in Pharmacological Sciences</u> , "A Therapeutic Role for Cannabinoid CB1 Receptor Antagonists in Major Depressive Disorders", Vol. 26, No. 12, pages 609-617 (2005)	
SM		Wolff, M., et al., <u>European Journal of Pharmacology</u> , "SR141716A, A Cannabinoid CB1 Receptor Antagonist, Improves Memory in a Delayed Radial Maze Task", Vol. 477, pages 213-217 (2003)	
SM		Louis, C., et al., <u>Psychopharmacology</u> , "Surinabant, a New CB1 Receptor Antagonist, Displays Efficacy in Animal Models of Attention Deficit/Hyperactivity Disorder", Vol. 30, S173, Abstract 77 (2005)	
EXAMINER /Susanna Moore/		DATE CONSIDERED	08/25/2006